Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SR9009||SR9009 is a synthetic agonist of REV-ERB nuclear receptors that may lead to suppression of tumorigenesis processes (PMID: 29320480).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||glioblastoma multiforme||not applicable||SR9009||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, SR9009 inhibited growth of glioblastoma cell lines in culture, resulted in apoptosis in tumors and prolonged survival in both cell line and patient-derived xenograft models (PMID: 29320480).||29320480|
|HRAS G12V||Advanced Solid Tumor||predicted - sensitive||SR9009||Preclinical - Cell culture||Actionable||In a preclinical study, SR9009 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).||29320480|
|Unknown unknown||Advanced Solid Tumor||not applicable||SR9009||Preclinical - Cell culture||Actionable||In a preclinicl study SR9009 demonstrated toxicity in a wide range of tumor cell lines harboring different driver mutations, but not in normal cell lines in culture (PMID: 29320480).||29320480|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|